Cargando…

1102. Evaluation of Vancomycin Accumulation in Patients with Obesity

BACKGROUND: Current vancomycin guidelines recommend using actual body weight for dosing. However, in patients with obesity, this may result in lower initial vancomycin concentrations that can accumulate with continued doses due to differences in volume of distribution. The objective of this study is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Assadoon, Maha, Pearson, Jeffrey C, Kubiak, David W, Kovacevic, Mary P, Dionne, Brandon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644315/ http://dx.doi.org/10.1093/ofid/ofab466.1296

Ejemplares similares

Evaluation of Vancomycin Accumulation in Patients With Obesity
por: Assadoon, Maha S, et al.
Publicado: (2022)

1326. Vancomycin Area Under the Concentration-Time Curve (AUC) Estimation Using a Bayesian Approach Versus First-Order Pharmacokinetic Equations: A Pilot Study
por: Pearson, Jeffrey, et al.
Publicado: (2020)

Vancomycin Area under the Concentration-Time Curve Estimation Using Bayesian Modeling versus First-Order Pharmacokinetic Equations: A Quasi-Experimental Study
por: Alsowaida, Yazed Saleh, et al.
Publicado: (2022)

329. Vancomycin area under the concentration-time curve monitoring from Bayesian modeling in outpatient parenteral antimicrobial therapy
por: Gillett, Eric M, et al.
Publicado: (2023)

1102. Reconstitution of CMV-specific cell-mediated immunity during letermovir prophylaxis in hematopoietic stem cell recipients
por: Abidi, Maheen, et al.
Publicado: (2020)

393 Vancomycin Dosing in Obese Patients
por: Alquwaizani, Mohammed, et al.
Publicado: (2014)

1102. Ertapenem vs. Nonertapenem Antibiotics in Colorectal Surgery: A Stewardship Opportunity
por: LaDow, Tiffany, et al.
Publicado: (2019)

301. Penicillin Versus Cefazolin or Anti-staphylococcal Penicillins for Penicillin-Susceptible Staphylococcus aureus Bacteremia
por: Aldhaeefi, Mohammed, et al.
Publicado: (2020)

1102. Pediatric Hepatitis C Screening by Maternal Hepatitis C Viral Load Status in Pregnancy
por: DiNicola, Julia, et al.
Publicado: (2023)

An Evaluation of Systemic Vancomycin Dosing in Obese Patients
por: Kubiak, David W., et al.
Publicado: (2015)

1108. Evaluation of Vancomycin Dosing in Adolescents
por: Weaver, Ashley I, et al.
Publicado: (2021)

1102. Food Insecurity and Reported History of Cholera in Haitian Households: An Analysis of the 2012 Demographic and Health Survey (DHS)
por: Richterman, Aaron, et al.
Publicado: (2018)

346. Evaluation of the Safety Profile of Cefazolin Monotherapy in Outpatient Parenteral Antibiotic Antimicrobial Therapy at a Large Academic Medical Center
por: Poux, Nicolas, et al.
Publicado: (2023)

227. Evaluation of Empiric Vancomycin Utilization at 72 Hours Post Admission: is De-escalation of Vancomycin Appropriate?
por: Naderi, Mandana, et al.
Publicado: (2020)

1091. Validation of an Allometrically Scaled Body Weight Equation to Predict Vancomycin Clearance and Guide 24-Hour Vancomycin AUC Dosing in Obese Patients
por: Footer, Brent, et al.
Publicado: (2021)

1096. Evaluation of Vancomycin Pharmacokinetics in Intravenous Drug Users
por: Weihs, Sayo, et al.
Publicado: (2021)

P1102: IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: UPDATED OUTCOMES FROM A MULTICENTRE, REAL-WORLD UK STUDY
por: Shotton, Rohan, et al.
Publicado: (2023)

O9.5. ABERRANT DOPAMINE SYSTEM FUNCTION REVERSED BY THE OREXIN RECEPTOR ANTAGONIST TCS1102 IN A RODENT MODEL OF SCHIZOPHRENIA
por: Perez, Stephanie, et al.
Publicado: (2018)

P1102: A PHASE 1 STUDY OF PARSACLISIB IN COMBINATION WITH RITUXIMAB, BENDAMUSTINE + RITUXIMAB, OR IBRUTINIB IN PATIENTS WITH PREVIOUSLY TREATED B-CELL LYMPHOMA (CITADEL-112): PRELIMINARY SAFETY RESULTS
por: Sancho, J.-M., et al.
Publicado: (2022)

608. Continuous Infusion Vancomycin Is Not Associated with Improved Safety in an Outpatient Parenteral Antimicrobial Therapy Program
por: Tagare, Rosemarie D, et al.
Publicado: (2021)

1024. Evaluation of Atovaquone Prescribing for Pneumocystis jiroveci Pneumonia (PJP) Prophylaxis
por: Aleissa, Muneerah, et al.
Publicado: (2019)

182. Missed Opportunities to Discontinue Unnecessary Vancomycin During Pharmacist Therapeutic Monitoring
por: Medler, Corey J, et al.
Publicado: (2020)

1090. Does calculation method matter for targeting vancomycin AUC?
por: Chang, Jack, et al.
Publicado: (2021)

1586. A Comparative Analysis of In Vitro Susceptibilities of Vancomycin-Resistant Enterococci Against Doxycycline, Minocycline, Tigecycline, Eravacycline and Omadacycline
por: Chua, Mary Francine P, et al.
Publicado: (2020)

881. Efficacy of Antibiotic Prophylaxis with Vancomycin in Cardiothoracic Surgery
por: Cooper, Margaret, et al.
Publicado: (2020)

200. Real-World Experience with Dalbavancin for Complicated Gram-Positive Infections: A Multicenter Evaluation
por: Alosaimy, Sara, et al.
Publicado: (2019)

187. Vancomycin Plus Ceftaroline Salvage Therapy for Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia
por: Kufel, Wesley D, et al.
Publicado: (2021)

763. Impact of Two-Step Testing Algorithm on Hospital-onset Clostridioides difficile Infections and Oral Vancomycin Prescription Practices at an Academic Medical Center
por: Wingler, Mary Joyce, et al.
Publicado: (2021)

1329. Vancomycin Therapeutic Drug Monitoring: How to hit the Curve
por: Vala, Michael, et al.
Publicado: (2020)

1110. In Vivo Pharmacodynamics of Vancomycin Against Staphylococci in Young Infants
por: Gwee, Amanda, et al.
Publicado: (2021)

609. Implementation of Bayesian Software for Vancomycin Dosing Integrated into an Electronic Medical Record
por: Jantrakul, Nicholas A, et al.
Publicado: (2021)

1119. Assessment of Vancomycin Pharmacokinetic Parameters in Pediatric Patients After Liver Transplantation
por: Morales, Ronaldo, et al.
Publicado: (2021)

597. Comparison of Vancomycin and Daptomycin Complications and Interventions in Outpatient Parenteral Antimicrobial Therapy
por: Nakrani, Monark, et al.
Publicado: (2020)

162. Assessment of Beta-lactam Allergies as Rationale for Receipt of Vancomycin for Surgical Prophylaxis
por: Tucker, Kendall J, et al.
Publicado: (2020)

1323. Efficacy and Safety of Telavancin Compared to Vancomycin for Cystic Fibrosis Pulmonary Exacerbation in Adults
por: Shorman, Mahmoud, et al.
Publicado: (2021)

1611. Evaluating Clinical Outcomes and Efficacy of Daptomycin in Combination with a Beta-Lactam for the Treatment of Vancomycin-Resistant Enterococcus (VRE) Bacteremia
por: Irusta, Nerea, et al.
Publicado: (2020)

1354. Reducing vancomycin utilization rate in a level 4 NICU
por: Chang, Millie R, et al.
Publicado: (2020)

P17 Vancomycin therapeutic drug monitoring—a call for change?
por: Payne, Lara, et al.
Publicado: (2022)

1239. Ceftaroline versus Vancomycin as First-Line Therapy for MRSA Bacteremia
por: Kamath, Meghan, et al.
Publicado: (2021)

OA11.02. A model of integrative care for low back pain
por: Eisenberg, D, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_ghkqj7fvq5ngqs5t6103ie8ptn